Canadian Uro-Oncology Summit 2019
CUOS 2019 Prostate Cancer
- CUOS 2019: High-Risk Prostate Cancer Debate: Surgery
- CUOS 2019: High-Risk Prostate Cancer Debate: Radiation
- CUOS 2019: Sequencing Issues Around Androgen Receptor Pathway Inhibition
- CUOS 2019: Treating M0 or Non-metastatic Castration-resistant Prostate Cancer
- CUOS 2019: Is There a Role for Treating the Primary in Metastatic Hormone-sensitive Prostate Cancer
CUOS 2019 Bladder Cancer
- CUOS 2019: Bladder Preservation for Invasive Bladder Cancer: Lessons Learned and Future Perspectives
- CUOS 2019: High-grade Upper Tract Urothelial Carcinoma – Adjuvant Chemotherapy
- CUOS 2019: High-grade Upper Tract Urothelial Carcinoma – Neoadjuvant Chemotherapy
- CUOS 2019: Neoadjuvant Chemotherapy Guided by Molecular Subtyping
- CUOS 2019: Neoadjuvant Chemotherapy for All Muscle-Invasive Bladder Cancer
CUOS 2019 Kidney Cancer
- CUOS 2019: Biopsy of the Small Renal Mass - Still Controversial?
- CUOS 2019: Cytoreductive Nephrectomy: Is There Still a Role for Nephrectomy in Patients with Metastatic RCC?
- CUOS 2019: Lymph Node Dissection at the Time of Nephrectomy - CON
- CUOS 2019: Lymph Node Dissection at the Time of Nephrectomy - PRO